2026-01-15 - Analysis Report
**Company Overview:**
Amgen Inc is a multinational bioscience company specializing in human therapeutics.

**Return Rate Comparison:**

* Cumulative Return of Review Stock (AMGN): **70.26%**
* Cumulative Return of Comparison Stock (S&P 500, VOO): **92.89%**
* Degree of Divergence: **22.63%** (92.89 - 70.26)

**Alpha, Beta Analysis:**

| Year | CAGR | MDD | Alpha | Beta | Cap(B) |
| --- | --- | --- | --- | --- | --- |
| 2016-2018 | 14.0% | 14.6% | 11.0% | 1.1 | 104.8B |
| 2017-2019 | 41.0% | 12.4% | 24.0% | 0.9 | 129.8B |
| 2018-2020 | 8.0% | 17.7% | -13.0% | 0.8 | 123.8B |
| 2019-2021 | 15.0% | 17.7% | -28.0% | 0.8 | 121.1B |
| 2020-2022 | 15.0% | 15.5% | 17.0% | 0.6 | 141.4B |
| 2021-2023 | 19.0% | 15.3% | 19.0% | 0.4 | 155.1B |
| 2022-2024 | 12.0% | 21.0% | -8.0% | 0.4 | 140.3B |
| 2023-2025 | 38.0% | 21.0% | -24.0% | 0.5 | 176.2B |

**Stock Price Fluctuations:**

* Latest Market Close: **$328.97**
* 20-Day SMA: **$328.76**
* 60-Day SMA: **$323.58**
* Recent Fluctuation: Small rebound.

**Indicators and Diversion Analysis:**

* Market Risk Indicator (MRI): **0.70**
* Relative Strength Index (RSI): **47.88**
* Percentage Price Oscillator (PPO): **-0.15**
* Recent Relative Divergence Change: **Worsening by -5.00**
* Expected Return: **-2.50%** compared to S&P 500.
* 7-Day Rank Change: **Flat (0).**
* 7-Day Dynamic Expected Return Change: **Flat (0).**

**Recent News & Significant Events:**

* Amgen Inc. (NASDAQ:AMGN) Shares Could Be 49% Below Their Intrinsic Value Estimate - Yahoo Finance (link)
* ...other recent headlines.

**Analyst Opinions:**

Analyst Consensus:
* Key: Buy
* Mean (1=StrongBuy~5=Sell): **2.41** (~Buy)
* Opinions: **27**
* Target Price (avg/high/low): **331.59 / 425.00 / 180.00**

**Recent Earnings Analysis:**

| Date | EPS | Revenue |
| ---:| ---:| ---: |
| 2025-11-05 | 5.98 | 9.56B$ |
| 2025-08-06 | 2.66 | 9.18B$ |
| 2025-05-02 | 3.22 | 8.15B$ |
| 2024-10-31 | 5.27 | 8.50B$ |
| 2025-11-05 | 5.27 | 8.50B$ |

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
| ---| ---:| ---:|
| 2025-09-30 | 9.56B | 67.75% |
| 2025-06-30 | 9.18B | 67.20% |
| 2025-03-31 | 8.15B | 63.58% |
| 2024-12-31 | 9.09B | 65.75% |
| 2024-09-30 | 8.50B | 61.07% |

**Capital and Profitability:**

| Quarter | Equity | ROE |
| ---| ---:| ---:|
| 2025-09-30 | 9.62B | 33.43% |
| 2025-06-30 | 7.43B | 19.28% |
| 2025-03-31 | 6.21B | 27.87% |
| 2024-12-31 | 5.88B | 10.67% |
| 2024-09-30 | 7.53B | 37.60% |

**Comprehensive Analysis:**

Based on the analysis of the provided data, Amgen Inc has shown a relatively stable cumulative return over the past few years, although it lags behind the S&P 500. The stock has a relatively high market capitalization and a stable financial profile. The EPS and revenue have been fluctuating, indicating potential volatility. The analysts' opinions suggest a generally positive outlook, but the expected return compared to S&P 500 is negative.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.